[go: up one dir, main page]

EP2016162A4 - Anticorps monoclonaux humanisés contre le facteur de croissance des hépatocytes - Google Patents

Anticorps monoclonaux humanisés contre le facteur de croissance des hépatocytes

Info

Publication number
EP2016162A4
EP2016162A4 EP07759598A EP07759598A EP2016162A4 EP 2016162 A4 EP2016162 A4 EP 2016162A4 EP 07759598 A EP07759598 A EP 07759598A EP 07759598 A EP07759598 A EP 07759598A EP 2016162 A4 EP2016162 A4 EP 2016162A4
Authority
EP
European Patent Office
Prior art keywords
growth factor
monoclonal antibodies
hepatocyte growth
humanized monoclonal
humanized
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP07759598A
Other languages
German (de)
English (en)
Other versions
EP2016162B1 (fr
EP2016162A2 (fr
Inventor
Kyung Jin Kim
Lihong Wang
Hangil Park
Maximiliano Vasquez
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Galaxy Biotech LLC
Original Assignee
Galaxy Biotech LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galaxy Biotech LLC filed Critical Galaxy Biotech LLC
Priority to EP11192887A priority Critical patent/EP2476704A3/fr
Publication of EP2016162A2 publication Critical patent/EP2016162A2/fr
Publication of EP2016162A4 publication Critical patent/EP2016162A4/fr
Application granted granted Critical
Publication of EP2016162B1 publication Critical patent/EP2016162B1/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
EP07759598.1A 2006-04-01 2007-03-28 Anticorps monoclonaux humanisés contre le facteur de croissance des hépatocytes Active EP2016162B1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP11192887A EP2476704A3 (fr) 2006-04-01 2007-03-28 Anticorps monoclonaux humanisés du facteur de croissance des hépatocytes

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US78824306P 2006-04-01 2006-04-01
PCT/US2007/065385 WO2007115049A2 (fr) 2006-04-01 2007-03-28 Anticorps monoclonaux humanisés contre le facteur de croissance des hépatocytes

Related Child Applications (1)

Application Number Title Priority Date Filing Date
EP11192887A Division-Into EP2476704A3 (fr) 2006-04-01 2007-03-28 Anticorps monoclonaux humanisés du facteur de croissance des hépatocytes

Publications (3)

Publication Number Publication Date
EP2016162A2 EP2016162A2 (fr) 2009-01-21
EP2016162A4 true EP2016162A4 (fr) 2009-11-11
EP2016162B1 EP2016162B1 (fr) 2014-04-16

Family

ID=38564195

Family Applications (2)

Application Number Title Priority Date Filing Date
EP07759598.1A Active EP2016162B1 (fr) 2006-04-01 2007-03-28 Anticorps monoclonaux humanisés contre le facteur de croissance des hépatocytes
EP11192887A Withdrawn EP2476704A3 (fr) 2006-04-01 2007-03-28 Anticorps monoclonaux humanisés du facteur de croissance des hépatocytes

Family Applications After (1)

Application Number Title Priority Date Filing Date
EP11192887A Withdrawn EP2476704A3 (fr) 2006-04-01 2007-03-28 Anticorps monoclonaux humanisés du facteur de croissance des hépatocytes

Country Status (25)

Country Link
US (3) US7632926B2 (fr)
EP (2) EP2016162B1 (fr)
JP (1) JP5312315B2 (fr)
KR (1) KR101516289B1 (fr)
CN (2) CN103172736A (fr)
AR (1) AR059922A1 (fr)
AU (1) AU2007233242B2 (fr)
BR (1) BRPI0709932A2 (fr)
CA (1) CA2645358C (fr)
CO (1) CO6140067A2 (fr)
CR (1) CR10308A (fr)
ES (1) ES2465668T3 (fr)
GE (1) GEP20125517B (fr)
IL (1) IL194221A (fr)
MA (1) MA30382B1 (fr)
MX (1) MX2008012619A (fr)
MY (1) MY145042A (fr)
NO (1) NO20084539L (fr)
NZ (1) NZ571132A (fr)
PE (1) PE20080008A1 (fr)
RU (1) RU2461570C2 (fr)
TW (1) TWI417300B (fr)
UA (1) UA94452C2 (fr)
WO (1) WO2007115049A2 (fr)
ZA (1) ZA200807903B (fr)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040208876A1 (en) * 2003-04-18 2004-10-21 Kim Kyung Jin Monoclonal antibodies to hepatocyte growth factor
AR042955A1 (es) 2003-07-18 2005-07-13 Amgen Inc Agentes de union especifica al factor de crecimiento de hepatocitos
MX2007015056A (es) * 2005-06-02 2008-03-11 Galaxy Biotech Llc Metodos para el tratamiento de tumores de cerebro con anticuerpos.
AR059922A1 (es) 2006-04-01 2008-05-07 Galaxy Biotech Llc Anticuerpos monoclonales humanizados para el factor de crecimiento de hepatocitos
BRPI0712222B1 (pt) 2006-06-02 2021-10-13 Aveo Pharmaceuticals, Inc. Proteína de ligação isolada que se liga ao fator de crescimento de hepatócito humano (hgf), seu uso e método de produção, ácido nucléico, vetor de expressão, célula hospedeira, e métodos para produzir um polipeptídeo que compreende uma região variável da cadeia pesada de imunoglobulina e para produzir um polipeptídeo que compreende uma região variável da cadeia leve de imunoglobulina
NZ573819A (en) 2006-06-02 2011-09-30 Aveo Pharmaceuticals Inc Hepatocyte growth factor (hgf) binding proteins
JP2009539403A (ja) 2006-06-13 2009-11-19 オンコメッド ファーマシューティカルズ インコーポレイテッド 癌を診断および処置するための組成物および方法
US8088617B2 (en) 2007-01-24 2012-01-03 Oncomed Pharmaceuticals, Inc. Antibodies that bind the glutamate ligand binding region of Notch1
AU2009221808A1 (en) * 2008-03-06 2009-09-11 Genentech, Inc. Combination therapy with c-met and EGFR antagonists
CN102083615B (zh) * 2008-04-10 2014-08-13 战略系统有限公司 用于三维模型打印的系统和方法
TW200948380A (en) * 2008-04-11 2009-12-01 Galaxy Biotech Llc Combination of HGF inhibitor and PTEN agonist to treat cancer
CL2009000843A1 (es) * 2008-04-11 2009-07-24 Galaxy Biotech Llc Metodo para tratar cancer en un paciente que comprende la administracion de un primer agente que es inhibidor de factor de crecimiento de hepatocito (hgf) en combinacion con un segundo agente que es inhibidor de una ruta de senalizacion celular diferente de la ruta hgf/cmet.
US20110217294A1 (en) * 2008-04-11 2011-09-08 Daniel Fults Combination of hgf inhibitor and hedgehog inhibitor to treat cancer
AU2009246263B2 (en) * 2008-05-14 2014-08-21 Amgen Inc. Combinations VEGF(R) inhibitors and hepatocyte growth factor (c-Met) inhibitors for the treatment of cancer
CA2725873C (fr) 2008-05-29 2018-05-01 Galaxy Biotech, Llc Anticorps monoclonaux diriges contre un facteur de croissance fibroblastique basique
CA2729306C (fr) 2008-07-08 2015-08-18 Oncomed Pharmaceuticals, Inc. Agents de liaison de notch et antagonistes de notch ainsi que procedes d'utilisation correspondants
US9132189B2 (en) 2008-07-08 2015-09-15 Oncomed Pharmaceuticals, Inc. Notch1 binding agents and methods of use thereof
US8834875B2 (en) 2010-01-13 2014-09-16 Oncomed Pharmaceuticals, Inc. Notch1 binding agents and methods of use thereof
PL2842573T3 (pl) 2008-11-07 2018-04-30 Galaxy Biotech, Llc Przeciwciała monoklonalne swoiste dla receptora 2 czynnika wzrostu fibroblastów
WO2010071208A1 (fr) 2008-12-19 2010-06-24 武田薬品工業株式会社 Méthode de purification d'anticorps
WO2010119991A2 (fr) 2009-04-17 2010-10-21 Takeda Pharmaceutical Company Limited Nouveau procédé de traitement anticancéreux
WO2010136482A1 (fr) * 2009-05-28 2010-12-02 Glaxo Group Limited Protéines se liant à un antigène
KR101814571B1 (ko) 2010-03-10 2018-01-04 젠맵 에이/에스 Ｃ―ｍｅｔ에 대한 모노클로날 항체
WO2012003338A1 (fr) 2010-07-01 2012-01-05 Takeda Pharmaceutical Company Limited Combinaison d'un inhibiteur de cmet et d'un anticorps dirigé contre hgf et/ou cmet
US20140057908A1 (en) 2010-09-27 2014-02-27 Exelixis, Inc. Method of Treating Cancer
WO2012069557A1 (fr) * 2010-11-24 2012-05-31 Glaxo Group Limited Protéines multispécifique se liant à un antigène et ciblant hgf
EP2753357A1 (fr) 2011-09-09 2014-07-16 Amgen Inc. Utilisation de la protéine c-met pour prédire l'efficacité d'anticorps anti-facteur de croissance des hépatocytes (« hgf ») chez des patients atteints d'un cancer de l' sophage et de l'estomac
WO2013152252A1 (fr) 2012-04-06 2013-10-10 OSI Pharmaceuticals, LLC Polythérapie antinéoplasique
WO2014010586A1 (fr) 2012-07-10 2014-01-16 武田薬品工業株式会社 Préparation pharmaceutique pour l'injection
EP2708556B1 (fr) 2012-09-12 2018-11-07 Samsung Electronics Co., Ltd Composition pharmaceutique à utiliser dans une thérapie combinée pour la prévention ou le traitement des maladies induites par c-met ou le facteur d'angiogénèse
US9732150B2 (en) 2013-03-14 2017-08-15 Alderbio Holdings Llc Therapeutic use of antibodies to HGF
US9062104B2 (en) 2013-03-14 2015-06-23 Alderbio Holdings Llc Therapeutic use of antibodies to HGF
TW201444868A (zh) * 2013-03-14 2014-12-01 Alder Biopharmaceuticals Inc Ｈｇｆ抗體及其組成物
CN107002119A (zh) 2014-03-24 2017-08-01 豪夫迈·罗氏有限公司 使用c‑met拮抗剂的癌症治疗及前者与hgf表达的关联
CA3003033A1 (fr) 2015-10-30 2017-05-04 Galaxy Biotech, Llc Anticorps hautement puissants se liant au recepteur de mort 4 et au recepteur de mort 5
BR112018067522A2 (pt) 2016-03-01 2019-02-05 Univ Of Rijeka Faculty Of Medicine anticorpos específicos para receptor de poliovírus humano (pvr)
AU2020327537A1 (en) 2019-08-12 2022-03-03 Interna Technologies B.V. New treatments involving miRNA-193a
EP4110917A1 (fr) 2020-02-28 2023-01-04 InteRNA Technologies B.V. Miarn-193a pour favoriser la mort cellulaire immunogène
CN113980129B (zh) * 2021-01-15 2023-07-28 东大生物技术(苏州)有限公司 一组il-11单克隆抗体及其医药用途
CN119285785B (zh) * 2024-09-26 2025-04-18 武汉奥科博泰生物科技有限公司 一种抗d-二聚体单克隆抗体及其应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US20040208876A1 (en) * 2003-04-18 2004-10-21 Kim Kyung Jin Monoclonal antibodies to hepatocyte growth factor

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2564486B2 (ja) * 1986-07-14 1996-12-18 修治 橋本 肝細胞増殖因子
EP0307434B2 (fr) 1987-03-18 1998-07-29 Scotgen Biopharmaceuticals, Inc. Anticorps alteres
US5859205A (en) * 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
EP1690935A3 (fr) 1990-01-12 2008-07-30 Abgenix, Inc. Génération d'anticorps xenogéniques
GB9009548D0 (en) 1990-04-27 1990-06-20 Celltech Ltd Chimeric antibody and method
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
ES2139598T3 (es) 1990-07-10 2000-02-16 Medical Res Council Procedimientos para la produccion de miembros de parejas de union especifica.
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
WO1993012227A1 (fr) 1991-12-17 1993-06-24 Genpharm International, Inc. Animaux transgeniques non humains capables de produire des anticorps heterologues
CA2103059C (fr) * 1991-06-14 2005-03-22 Paul J. Carter Methode de production d'anticorps humanises
US5837676A (en) * 1993-10-18 1998-11-17 Long Island Jewish Medical Center Use of scatter factor to enhance angiogenesis
US6498144B1 (en) * 1993-10-18 2002-12-24 North Shore - Long Island Jewish Research Institute Use of scatter factor to enhance angiogenesis
US5707624A (en) * 1994-06-03 1998-01-13 The Regents Of The University Of Michigan Treatment of Kaposi's sarcoma by inhibition of scatter factor
US6214344B1 (en) * 1995-06-02 2001-04-10 Genetech, Inc. Hepatocyte growth factor receptor antagonists and uses thereof
US5646036A (en) * 1995-06-02 1997-07-08 Genentech, Inc. Nucleic acids encoding hepatocyte growth factor receptor antagonist antibodies
US5686292A (en) * 1995-06-02 1997-11-11 Genentech, Inc. Hepatocyte growth factor receptor antagonist antibodies and uses thereof
US5834597A (en) 1996-05-20 1998-11-10 Protein Design Labs, Inc. Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same
ATE465257T1 (de) * 1996-07-03 2010-05-15 Genentech Inc Agonisten für den rezeptor des hepatozyten- wachstumsfaktors und deren anwendungen
JP2003502025A (ja) * 1999-05-17 2003-01-21 エイブイアイ バイオファーマ， インコーポレイテッド ｈｃＧワクチンを用いた癌の処置のための併用アプローチ
WO2001034650A1 (fr) 1999-11-09 2001-05-17 The Government Of The United States Of America, As Represented By The Secretary, Department Of Heatlh And Human Services Combinaison d'anticorps monoclonaux hgf-sf
EP1423432A4 (fr) 2001-07-26 2006-01-11 Lilly Co Eli Anticorps vis-a-vis de l'interleukine 1 beta (il-1beta)
WO2003057155A2 (fr) 2001-12-27 2003-07-17 Van Andel Research Institute Imagerie par anticorps monoclonaux et traitement de tumeurs exprimant met et se liant au facteur de croissance des hepatocytes
WO2004019991A2 (fr) * 2002-08-30 2004-03-11 F. Hoffmann-La Roche Ag Antagoniste nk4 du facteur de croissance de l'hepatocyte/du facteur de dispersion pour le traitement de gliome
AU2003900180A0 (en) * 2003-01-16 2003-01-30 Silverbrook Research Pty Ltd Method and apparatus (dam001)
US7220410B2 (en) * 2003-04-18 2007-05-22 Galaxy Biotech, Llc Monoclonal antibodies to hepatocyte growth factor
ATE425463T1 (de) 2003-06-06 2009-03-15 Genentech Inc Modulation der wechselwirkung zwischen hgf-beta- kette und c-met
US20070020234A1 (en) 2003-07-07 2007-01-25 Vande Woude George F Inhibition of tumor angiogenesis by combination of thrombospondin-1 and inhibitors of vascular endothelial growth factor
AR042955A1 (es) 2003-07-18 2005-07-13 Amgen Inc Agentes de union especifica al factor de crecimiento de hepatocitos
US20070030790A1 (en) 2003-09-18 2007-02-08 Koninklijke Philips Electronics N.V. Information carrier and system for reading data stored on such an information carrier
ES2651730T3 (es) 2003-09-26 2018-01-29 Exelixis, Inc. Moduladores c-Met y métodos de uso
KR100556660B1 (ko) 2003-11-11 2006-03-10 국립암센터 Ｈｇｆ의 중화가능 에피토프 및 이에 결합하는 중화 항체
WO2005079489A2 (fr) * 2004-02-17 2005-09-01 Science & Technology Corporation @ Unm Procede pour traiter le cancer et identifier de nouveaux composes anticancereux
EP1773826A4 (fr) 2004-07-02 2009-06-03 Exelixis Inc Modulateurs de c-met et leur methode d'utilisation
MX2007015056A (es) 2005-06-02 2008-03-11 Galaxy Biotech Llc Metodos para el tratamiento de tumores de cerebro con anticuerpos.
US7964365B2 (en) 2005-11-08 2011-06-21 The United States of Americam as represented by the Secretary, Department of Health and Human Services Methods for diagnosing and monitoring the progression of cancer
AR059922A1 (es) 2006-04-01 2008-05-07 Galaxy Biotech Llc Anticuerpos monoclonales humanizados para el factor de crecimiento de hepatocitos

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US20040208876A1 (en) * 2003-04-18 2004-10-21 Kim Kyung Jin Monoclonal antibodies to hepatocyte growth factor

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
BURGESS TERESA ET AL: "FULLY HUMAN MONOCLONAL ANTIBODIES TO HEPATOCYTE GROWTH FACTOR WITH THERAPEUTIC POTENTIAL AGAINST HEPATOCYTE GROWTH FACTOR/C-MET-DEPENDENT HUMAN TUMORS", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, BALTIMORE, MD., US, vol. 66, no. 3, 1 February 2006 (2006-02-01), pages 1721 - 1729, XP008075112, ISSN: 0008-5472 *
KASHMIRI S V S ET AL: "SDR grafting-a new approach to antibody humanization", METHODS : A COMPANION TO METHODS IN ENZYMOLOGY, ACADEMIC PRESS INC., NEW YORK, NY, US, vol. 36, no. 1, 1 May 2005 (2005-05-01), pages 25 - 34, XP004852550, ISSN: 1046-2023 *
KIM ET AL: "Antibody engineering for the development of therapeutic antibodies", MOLECULES AND CELLS, vol. 20, no. 1, 2005, pages 17 - 29, XP002540664 *
PRESTA L G ET AL: "Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, BALTIMORE, MD., US, vol. 57, no. 20, 15 October 1997 (1997-10-15), pages 4593 - 4599, XP002111212, ISSN: 0008-5472 *
TSURUSHITA N ET AL: "Design of humanized antibodies: From anti-Tac to Zenapax", METHODS : A COMPANION TO METHODS IN ENZYMOLOGY, ACADEMIC PRESS INC., NEW YORK, NY, US, vol. 36, no. 1, 1 May 2005 (2005-05-01), pages 69 - 83, XP004852554, ISSN: 1046-2023 *

Also Published As

Publication number Publication date
AU2007233242A1 (en) 2007-10-11
CO6140067A2 (es) 2010-03-19
BRPI0709932A2 (pt) 2011-08-02
CN101415811A (zh) 2009-04-22
CN101415811B (zh) 2013-01-30
US20080019974A1 (en) 2008-01-24
CA2645358A1 (fr) 2007-10-11
ES2465668T3 (es) 2014-06-06
IL194221A (en) 2015-11-30
RU2461570C2 (ru) 2012-09-20
JP5312315B2 (ja) 2013-10-09
UA94452C2 (ru) 2011-05-10
CR10308A (es) 2008-10-27
EP2476704A3 (fr) 2012-07-25
EP2016162B1 (fr) 2014-04-16
MY145042A (en) 2011-12-15
US20100278815A1 (en) 2010-11-04
WO2007115049A2 (fr) 2007-10-11
US7632926B2 (en) 2009-12-15
KR101516289B1 (ko) 2015-05-07
WO2007115049A3 (fr) 2008-09-04
RU2008143318A (ru) 2010-05-10
TW200808828A (en) 2008-02-16
GEP20125517B (en) 2012-05-25
EP2476704A2 (fr) 2012-07-18
CN103172736A (zh) 2013-06-26
KR20090013777A (ko) 2009-02-05
NZ571132A (en) 2012-05-25
AR059922A1 (es) 2008-05-07
ZA200807903B (en) 2010-03-31
PE20080008A1 (es) 2008-02-14
EP2016162A2 (fr) 2009-01-21
JP2009532378A (ja) 2009-09-10
HK1121489A1 (en) 2009-04-24
NO20084539L (no) 2008-10-28
CA2645358C (fr) 2015-05-05
MA30382B1 (fr) 2009-05-04
MX2008012619A (es) 2008-10-13
US8628778B2 (en) 2014-01-14
US20140335076A1 (en) 2014-11-13
AU2007233242B2 (en) 2012-04-26
TWI417300B (zh) 2013-12-01

Similar Documents

Publication Publication Date Title
ZA200807903B (en) Humanized monoclonal antibodies to hepatocyte growth factor
IL239947A0 (en) Monoclonal antibodies against 21-il of human origin
IL202232A0 (en) Novel rabbit antibody humanization methods and humanized rabbit antibodies
HRP20171640T1 (hr) Monoklonska protutijela za receptor faktora rasta fibroblasta 2
EP2349331A4 (fr) Anticorps anti-il-6 humanisés
EP2331579A4 (fr) Anticorps monoclonaux
IL182012A0 (en) Monoclonal antibodies to progastrin
ZA200809662B (en) Modified humanised anti-interleukin-18 antibodies
ZA200809065B (en) Humanized c-Kit antibody
IL207217A0 (en) Humanized anti-c5ar antibodies
SG10201601279SA (en) Monoclonal Antibody STRO-4
IL200168A0 (en) Monoclonal anti-cxcl13 antibodies
IL204835A0 (en) Humanized antibody
IL206639A0 (en) Humanized anti-human nkg2a monoclonal antibody
IL200437A0 (en) Anti-sclerostin antibodies
PL2195026T3 (pl) Przeciwciała przeciw sklerostynie
ZA200907220B (en) Novel fully human anti-VAP-1 monoclonal antibodies
EP2198055A4 (fr) Anticorps pai-1 humanisés
ZA201004770B (en) Improved humanized anti-human x9-integrin antibody
TWI348915B (en) Anti-vegf monoclonal antibody
GB0706965D0 (en) Humanized antibody
GB0706963D0 (en) Humanized antibody
GB0706964D0 (en) Humanized antibody
HK1147206A (en) Anti-human il-21 monoclonal antibodies

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20081029

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA HR MK RS

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1121489

Country of ref document: HK

RIC1 Information provided on ipc code assigned before grant

Ipc: C07K 16/18 20060101ALI20090908BHEP

Ipc: C07K 16/22 20060101AFI20090908BHEP

Ipc: A61K 39/395 20060101ALI20090908BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20090914

17Q First examination report despatched

Effective date: 20091130

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

RIN1 Information on inventor provided before grant (corrected)

Inventor name: WANG, LIHONG

Inventor name: VASQUEZ, MAXIMILIANO

Inventor name: PARK, HANGIL

Inventor name: KIM, KYUNG, JIN

INTG Intention to grant announced

Effective date: 20131126

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA HR MK RS

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: AT

Ref legal event code: REF

Ref document number: 662510

Country of ref document: AT

Kind code of ref document: T

Effective date: 20140515

Ref country code: CH

Ref legal event code: NV

Representative=s name: E. BLUM AND CO. AG PATENT- UND MARKENANWAELTE , CH

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

Ref country code: NL

Ref legal event code: T3

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602007036130

Country of ref document: DE

Effective date: 20140528

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2465668

Country of ref document: ES

Kind code of ref document: T3

Effective date: 20140606

REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1121489

Country of ref document: HK

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK05

Ref document number: 662510

Country of ref document: AT

Kind code of ref document: T

Effective date: 20140416

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG4D

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140416

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140416

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140717

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140716

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140416

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140816

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140416

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140416

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140416

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140416

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140818

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602007036130

Country of ref document: DE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140416

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140416

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140416

Ref country code: BE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140416

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140416

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140416

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 9

26N No opposition filed

Effective date: 20150119

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CH

Payment date: 20150313

Year of fee payment: 9

Ref country code: IE

Payment date: 20150309

Year of fee payment: 9

Ref country code: DE

Payment date: 20150324

Year of fee payment: 9

Ref country code: ES

Payment date: 20150212

Year of fee payment: 9

Ref country code: IT

Payment date: 20150224

Year of fee payment: 9

Ref country code: NL

Payment date: 20150309

Year of fee payment: 9

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602007036130

Country of ref document: DE

Effective date: 20150119

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20150309

Year of fee payment: 9

Ref country code: GB

Payment date: 20150325

Year of fee payment: 9

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140416

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140416

Ref country code: LU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150328

REG Reference to a national code

Ref country code: DE

Ref legal event code: R119

Ref document number: 602007036130

Country of ref document: DE

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

REG Reference to a national code

Ref country code: NL

Ref legal event code: MM

Effective date: 20160401

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20160328

REG Reference to a national code

Ref country code: IE

Ref legal event code: MM4A

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140416

REG Reference to a national code

Ref country code: FR

Ref legal event code: ST

Effective date: 20161130

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20161001

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20160328

Ref country code: NL

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20160401

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20160328

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20160331

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20160331

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20160331

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20160328

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: HU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO

Effective date: 20070328

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140416

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20160329

REG Reference to a national code

Ref country code: ES

Ref legal event code: FD2A

Effective date: 20180622